Payment overview · 2025
General Payments
$224.07
10 reported records · 7 companies
Healthcare provider profile · identity verified
Prita Bhardwaj, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MANASSAS, VA · NPI 1790092922
Verified facts
What the public records show
CMS Open Payments records show Prita Bhardwaj, MD received $224.07 in general payments during 2025 across 10 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 22.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rexulti.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 2902 records involving 986 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Abilify Maintena by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Abilify Maintena by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $51.34 | 22.9% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $46.04 | 20.6% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $40.63 | 18.1% | 2 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $31.59 | 14.1% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $20.18 | 9.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.45 | 8.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.84 | 6.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $224.07 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $51.34 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $40.63 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $35.02 | 2 | 2025 |
Source payment records
|
|||||
| TERIPARATIDE Normalized: teriparatide |
Drug | Almatica Pharma LLC | $31.59 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $23.07 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $22.97 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.45 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.45 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 71 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
71 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 2902 supporting records · 986 recipient NPIs · example record 1251759994 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 353 | 63 |
| Atorvastatin Calcium | Atorvastatin Calcium | 333 | 70 |
| Amlodipine Besylate | Amlodipine Besylate | 318 | 56 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 285 | 47 |
| Furosemide | Furosemide | 274 | 43 |
| Losartan Potassium | Losartan Potassium | 251 | 44 |
| Eliquis | Apixaban | 238 | 33 |
| Metformin Hcl | Metformin Hcl | 238 | 36 |
| Donepezil Hcl | Donepezil Hcl | 215 | 36 |
| Quetiapine Fumarate | Quetiapine Fumarate | 215 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 209 | 30 |
| Gabapentin | Gabapentin | 202 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 200 | 35 |
| Trazodone Hcl | Trazodone Hcl | 187 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 146 | 24 |
| Warfarin Sodium | Warfarin Sodium | 145 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 129 | 28 |
| Sertraline Hcl | Sertraline Hcl | 127 | 21 |
| Memantine Hcl | Memantine Hcl | 122 | 18 |
| Lisinopril | Lisinopril | 119 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 103 | 22 |
| Omeprazole | Omeprazole | 95 | 22 |
| Mirtazapine | Mirtazapine | 86 | 20 |
| Oxybutynin Chloride | Oxybutynin Chloride | 82 | suppressed |
| Allopurinol | Allopurinol | 77 | 13 |
| Myrbetriq | Mirabegron | 77 | suppressed |
| Mounjaro | Tirzepatide | 71 | suppressed |
| Carvedilol | Carvedilol | 69 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 66 | 13 |
| Latanoprost | Latanoprost | 63 | 12 |
| Divalproex Sodium | Divalproex Sodium | 62 | suppressed |
| Famotidine | Famotidine | 58 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 56 | 11 |
| Potassium Chloride | Potassium Chloride | 56 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 56 | 15 |
| Aripiprazole | Aripiprazole | 55 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 55 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 55 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 55 | 14 |
| Simvastatin | Simvastatin | 54 | suppressed |
| Alprazolam | Alprazolam | 51 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 51 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 13 |
| Olanzapine | Olanzapine | 50 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 49 | suppressed |
| Sucralfate | Sucralfate | 49 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | suppressed |
| Atenolol | Atenolol | 47 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 47 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 46 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 44 | 27 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 42 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 42 | 16 |
| Divalproex Sodium Er | Divalproex Sodium | 38 | suppressed |
| Ezetimibe | Ezetimibe | 37 | suppressed |
| Lorazepam | Lorazepam | 37 | 22 |
| Ozempic | Semaglutide | 37 | suppressed |
| Finasteride | Finasteride | 36 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 36 | suppressed |
| Nifedipine Er | Nifedipine | 35 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 34 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 34 | suppressed |
| Meloxicam | Meloxicam | 34 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 34 | suppressed |
| Nystatin | Nystatin | 34 | 13 |
| Glipizide | Glipizide | 33 | suppressed |
| Bumetanide | Bumetanide | 32 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 30 | suppressed |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 29 | suppressed |
| Prednisone | Prednisone | 28 | suppressed |
| Valsartan | Valsartan | 28 | suppressed |
| Azithromycin | Azithromycin | 27 | 21 |
| Folic Acid | Folic Acid | 27 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Klor-Con 10 | Potassium Chloride | 26 | suppressed |
| Risperidone | Risperidone | 26 | suppressed |
| Gemtesa | Vibegron | 25 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 25 | suppressed |
| Rexulti | Brexpiprazole | 24 | suppressed |
| Cephalexin | Cephalexin | 23 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Haloperidol | Haloperidol | 21 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 21 | suppressed |
| Restasis | Cyclosporine | 21 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Abilify Maintena | Aripiprazole | 20 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 20 | 15 |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Jardiance | Empagliflozin | 18 | suppressed |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 11 |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Budesonide | Budesonide | 15 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 15 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 14 | 14 |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Paliperidone Er | Paliperidone | 14 | suppressed |
| Rivastigmine | Rivastigmine | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Hydroxyurea | Hydroxyurea | 13 | suppressed |
| Insulin Glargine Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Lumigan | Bimatoprost | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Humulin R | Insulin Regular, Human | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Daptomycin | Daptomycin | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Mesalamine | Mesalamine | 11 | suppressed |
| Neomycin-Bacitracin-Polymyxin | Neomycin/Bacitracin/Polymyxinb | 11 | suppressed |
| Timolol Maleate | Timolol Maleate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $224.07 · 10 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA, KISUNLA, Kerendia, MOUNJARO, Ozempic, REXULTI, Rybelsus, TERIPARATIDE | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error